News
InvestorsHub on MSN7h
Merck Launches Final-Stage Trial of Dengue Vaccine for ChildrenMerck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback